Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to LantusĀ® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.

Reichstetter S, Castillo GM, Lai M, Nishimoto-Ashfield A, Banerjee A, Bogdanov A, Lyubimov AV, Bolotin EM.

Pharm Res. 2012 Apr;29(4):1033-9. doi: 10.1007/s11095-011-0646-8. Epub 2011 Dec 28.

PMID:
22203325
2.

Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.

Castillo GM, Reichstetter S, Bolotin EM.

Pharm Res. 2012 Jan;29(1):306-18. doi: 10.1007/s11095-011-0542-2. Epub 2011 Aug 4.

3.

Ten years of leptin replacement therapy.

Paz-Filho G, Wong ML, Licinio J.

Obes Rev. 2011 May;12(5):e315-23. doi: 10.1111/j.1467-789X.2010.00840.x. Epub 2011 Mar 17. Review.

PMID:
21410864
4.

Self-assembled micelles of novel graft amphiphilic copolymers for drug controlled release.

Xun W, Wang HY, Li ZY, Cheng SX, Zhang XZ, Zhuo RX.

Colloids Surf B Biointerfaces. 2011 Jun 15;85(1):86-91. doi: 10.1016/j.colsurfb.2010.10.036. Epub 2010 Oct 30.

PMID:
21087841
5.

New self-assembling polyaspartylhydrazide copolymer micelles for anticancer drug delivery.

Licciardi M, Cavallaro G, Di Stefano M, Pitarresi G, Fiorica C, Giammona G.

Int J Pharm. 2010 Aug 30;396(1-2):219-28. doi: 10.1016/j.ijpharm.2010.06.021. Epub 2010 Jun 19.

PMID:
20600731
6.

The toxicity of high molecular weight polyethylene glycols; chronic oral and parenteral administration.

SMYTH HF Jr, CARPENTER CP, SHAFFER CB.

J Am Pharm Assoc Am Pharm Assoc. 1947 May;36(5):157-60. No abstract available.

PMID:
20251050
7.

Passive and active drug targeting: drug delivery to tumors as an example.

Torchilin VP.

Handb Exp Pharmacol. 2010;(197):3-53. doi: 10.1007/978-3-642-00477-3_1. Review.

PMID:
20217525
8.

In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells.

Kang HW, Walvick R, Bogdanov A Jr.

FASEB J. 2009 Dec;23(12):4126-34. doi: 10.1096/fj.08-127795. Epub 2009 Aug 19.

9.

Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents.

Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M.

J Control Release. 2009 May 21;136(1):14-20. doi: 10.1016/j.jconrel.2009.01.010. Epub 2009 Jan 23.

PMID:
19331861
10.

Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo.

Kozloff KM, Quinti L, Patntirapong S, Hauschka PV, Tung CH, Weissleder R, Mahmood U.

Bone. 2009 Feb;44(2):190-8. doi: 10.1016/j.bone.2008.10.036. Epub 2008 Oct 22.

11.

In vivo quantification of transvascular water exchange during the acute phase of permanent stroke.

Kim YR, Tejima E, Huang S, Atochin DN, Dai G, Lo EH, Huang PL, Bogdanov A Jr, Rosen BR.

Magn Reson Med. 2008 Oct;60(4):813-21. doi: 10.1002/mrm.21708.

12.

Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts.

Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen YF.

Circ Res. 2008 Feb 1;102(2):185-92. Epub 2007 Nov 8.

13.

Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S; J-WIND investigators.

Lancet. 2007 Oct 27;370(9597):1483-93. Erratum in: Lancet. 2008 Dec 22;370(9605):2102.

PMID:
17964349
14.

Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes.

Medarova Z, Castillo G, Dai G, Bolotin E, Bogdanov A, Moore A.

Diabetes. 2007 Nov;56(11):2677-82. Epub 2007 Aug 6.

15.

Development of polymeric gene delivery carriers: PEGylated copolymers of L-lysine and L-phenylalanine.

Choi YR, Chae SY, Ahn CH, Lee M, Oh S, Byun Y, Rhee BD, Ko KS.

J Drug Target. 2007 Jul;15(6):391-8.

PMID:
17613657
16.

Selective antitumor effect of novel protease-mediated photodynamic agent.

Choi Y, Weissleder R, Tung CH.

Cancer Res. 2006 Jul 15;66(14):7225-9.

17.

In-vivo imaging of tumor associated urokinase-type plasminogen activator activity.

Hsiao JK, Law B, Weissleder R, Tung CH.

J Biomed Opt. 2006 May-Jun;11(3):34013.

PMID:
16822063
18.

Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo.

Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P.

Circulation. 2006 Jul 4;114(1):55-62. Epub 2006 Jun 26.

19.

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.

Cancer Res. 2005 Oct 15;65(20):9398-405.

20.

Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.

Kim YR, Yudina A, Figueiredo J, Reichardt W, Hu-Lowe D, Petrovsky A, Kang HW, Torres D, Mahmood U, Weissleder R, Bogdanov AA Jr.

Cancer Res. 2005 Oct 15;65(20):9253-60.

Supplemental Content

Support Center